All In Biotech

Drug Trial Radar · NCT03002935

A Safety Study of Orally Administered BPM31510 in Healthy Subjects

A Phase I Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Orally Administered BPM31510 in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Apr 5, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

25

Actual

Start

Jan 2017

Primary completion

Mar 2017

Study completion Mar 2017

Sponsor

Lead sponsor
BPGbioIndustry
Sponsor type
Industry
First posted
Dec 26, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is an open-label, Phase I study of the bioavailability and safety of BPM31510 administered orally in healthy subjects dosed 3 times daily for 14 days. The last study dose is administered on Day 15 (one morning dose only). The study will consist of 25 subjects.

Conditions

  • Healthy

Interventions

  • BPM31510 Oral Nanosuspension 4%Drug

    Oral nanosuspension formulation of BPM31510 (ubidecarenone, USP)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum plasma concentration (Cmax)Time frame: Days 1, 2, 5, 15; baseline pre-dosing concentrations
  2. Area under the plasma concentration curve (AUC0-4)Time frame: Days 1, 2, 5, 15; baseline pre-dosing concentrations

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinilabs Inc.

    Eatontown, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.